Form 4 Tracker
Benjamin Halladay

Chief Financial Officer · 3 filings · Latest: Jun 17, 2026

Esperion Therapeutics, Inc.
TickerOwnerRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Filing
ESPR
Benjamin HalladayChief Financial OfficerJun 17, 2026
Sale
$3.1510,773$34.0K702,829
ESPR
Halladay BenjaminJun 17, 2026
Proposed Sale
$3.1510,773$34.0K
ESPR
Benjamin HalladayChief Financial OfficerMar 17, 2026
Sale
$2.716,424$17.4K713,602
ESPR
Halladay BenjaminMar 17, 2026
Proposed Sale
$2.706,424$17.4K
ESPR
Halladay BenjaminDec 17, 2025
Proposed Sale
$3.677,337$26.9K
ESPR
Halladay BenjaminSep 17, 2025
Proposed Sale
$2.817,046$19.8K
ESPR
Halladay BenjaminJul 17, 2025
Proposed Sale
$1.1211$12
ESPR
Halladay BenjaminJun 17, 2025
Proposed Sale
$1.157,229$8.3K
ESPR
Halladay BenjaminApr 17, 2025
Proposed Sale
$0.96388$8
ESPR
Halladay BenjaminMar 18, 2025
Proposed Sale
$1.483,535$5.2K
ESPR
Halladay BenjaminFeb 19, 2025
Proposed Sale
$1.8611$20
ESPR
Halladay BenjaminJan 17, 2025
Proposed Sale
$2.259$20
ESPR
Halladay BenjaminDec 17, 2024
Proposed Sale
$2.423,245$7.9K